PBRM1 and nonpapillary renal cell carcinoma: The results revealed no significant difference in overall survival rates according to PD-L1 expression status in nivolumab-treated patients with ccRCC, although the patients enrolled in clinical trials exhibited a higher proportion of high PD-L1 mRNA levels in the high E27 functional group (RBFOX2 low and PBRM1 WT) compared to the low E27 functional group (all others) (Fig. EV5G,H).